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Background. Study examined the determinants of mortality among adult HIV patients in a rural, tertiary hospital in southeastern
Nigeria,comparingmortalityamongvariousARTregimens.Methods.Retrospectivecohortstudyof1069patientsonARTbetween
August 2008 and October 2013. Baseline CD4 counts, age, gender, and ART regimen were considered in this study. Kaplan-Meier
methodwasusedtoestimatesurvivalandCoxproportionalhazardsmodelstoidentifymultivariatepredictorsofmortality.Median
follow-up period was 24 months (IQR 6–45). Results. 78 (7.3%) patients died with 15.6% lost to followup. Significant independent
predictorsofmortalityincludeage(>45),sex(male>female),baselineCD4stage(<200),andARTcombination.Adjustedmortality
hazardwas3timeshigheramongpatientswithCD4count<200cells/𝜇Ltha nthosewi thco un ts>500(95%CI1.69–13.59).Patients
on Truvada-based first-line regimens were 88% more likely to die than those on Combivir-based first line (95% CI 1.05–3.36),
especially those with CD4 count <200cells/𝜇L. Conclusion. Study showed lower mortality than most studies in Nigeria and Africa,
with mortality higher among males and patients with CD4 count <200. Further studies are recommended to further compare
treatment outcomes between Combivir- and Truvada-based regimens in resource-limited settings using clinical indicators.
1. Introduction
In 2008, it was estimated that 33.4 million people were living
with HIV/AIDS worldwide, with about 70% of those in
sub-Saharan Africa [1]. Poor access to treatment services,
poverty,andignorancehavecontributedtothehighmortality
associated with this disease in the region [2]. Following
t h ed i s c o v e r yo ft h ed i s e a s ei nN i g e r i ai n1 9 8 6 ,t h e r eh a s
beensignificantdevelopmentineffortstocombatHIV/AIDS,
including scaling up of antiretroviral treatment (ARTs). This
increased the number of people accessing ARTs from 10,000
(2002) to 300,000 (2010) [3]. Nigerian Christian Hospital is
one such treatment facility that was activated in August 2008
in southeastern Nigeria.
However, few studies have been conducted to investigate
the determinants of mortality for people using ART services
in southeastern Nigeria. Onoka et al. studied HIV programs
in this region and reported loss-to-follow-up (LTFU) rate
between 11 and 32.8% [4]. They also showed that mortality
amongpatientsintheprogramsreviewedrangedfrom34.2%
to 56.7%. Males and patientsCD4 cell count≤200hadhigher
rates of LTFU; this study did not explore the pattern of
mortality based on drug treatment. Ogoina et al. studied
the pattern of morbidity and mortality among hospitalized
patients on ARTs [5]. This study estimated a mortality rate
of 31.9%, mostly due to disseminated tuberculosis and sepsis.
Death was higher among males and people with lower CD4-
cell count. There was no statistical difference in mortality
b a s e do np a r t i c i p a t i o ni nA R Tp r o g r a m .S o m er e s e a r c h e r s
(Bedavid et al. and Valen et al.) have also suggested that
Truvada-based 1st line regimen had better survival profile
than Combivir-based 1st line drugs [6, 7]. But, there is
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inconclusive evidence about the superiority of Truvada-
based regimens over Combivir-based regimens. Truvada-
based regimens have been found to be associated with less
toxicity and better dosing and enhance overall CD4 cells
recovery [6, 7].
Given the significant investment in various treatment
regimens in our center, this study sought to research into the
determinantsofmortalityforpeoplereceivingARTs.Abetter
knowledgeoftheprognosticfactorswillallowtailoredfollow-
up and better-targeted interventions in high-risk patients,
thus improving survival. The objective of this present study
was to analyze survival and to identify determinants of
mortality in HIV-infected adult patients taking ARTs in a
rural Nigerian hospital in the last 5 years. This study aimed
to examine the relative survival of patients on Combivir- and
Truvada-based regimens.
2. Methods
2.1. Study Setting and Participants. This study was conducted
in Nigerian Christian Hospital (NCH), a 110-bed faith-based
hospitalaffiliatedwiththeChurchofChristandInternational
HealthCareFoundation.Basedinaruralvillage,thehospital
isamajorhealthprovidertopeoplefromacrosssoutheastand
south-south Nigeria. It offers specialist services in Surgery,
ophthalmology, oncology, and internal medicine as well as
obstetrics and gynecology.
NCH commenced antiretroviral treatment (ART) pro-
gram in August 2008 under AIDSRelief consortium led
by Catholic Relief Services. Presently it has enrolled more
than 1,900 people living with HIV/AIDS in its program.
Services in this program include provision of voluntary
counselingandtesting,prevention-of-mother-to-childtrans-
mission (PMTCT), pediatric and nonpediatric ARTs, as well
as immunology. Most of the patients enrolled in the program
were recruited through antenatal care, voluntary testing,
referral, and in-patient hospitalization. A team of nurses
and community health officers as well as monitoring and
evaluation workers ensured patient followup and tracking of
appointments.
All patients were considered eligible for ART if they were
i nW H Oc l i n i c a ls t a g e3o r4i r r e s p e c t i v eo fC D 4c e l lc o u n t ;
if they were pregnant irrespective of CD4 count; and if they
had a CD4+ cell count ≤350cells/𝜇L. Other details of entry
criteria were per the National and WHO guidelines [3, 8].
Patients were given appointments ranging from monthly to
quarterly, and were monitored for adherence through home
v i s i t sa n df r e q u e n tp h o n ec a l l sa sw e l la sa t t e n d a n c ei n
support group meetings. All patients were assigned unique
identificationnumbers and were monitoredthroughIQ Care
software.
This is a retrospective, cohort study of all patients aged 15
years or older who are on ART (1st and 2nd line) in Nigerian
Christian Hospital between August 1, 2008, and October 25,
2013. The inclusion criteria were as follows: (1) subjects must
be HIV positive, ≥15 years of age, and enrolled at NCH,
and (2) subjects have commenced ART. It excluded patients
who were transferred to other treatment facilities during
the period. Approval for the study was obtained from the
Board of Nigerian Christian Hospital. Patient confidentiality
was maintained by using anonymized data extracted from
the database. Variables considered in our analysis were the
patient’s biological sex, age, baseline CD4 count, and current
treatment regimen.
2.2. Treatment, Monitoring, and Endpoints. Various highly
active antiretroviral therapy (HAART) was used in this
study period. First line treatment comprised combina-
tion of lamivudine-3TC and zidovudine-AZT as Combivir,
with either nevirapine (NVP) or efavirenz (EFV). Another
first line regimen was Truvada (emtricitabine/tenofovir-
FTC/TDF) with either nevirapine (NVP) or efavirenz (EFV).
R e g i m e nc h o i c ew a ss u b j e c tt oa v a i l a b i l i t y ,b a s e l i n eC D 4
count, pregnancy status, TB coinfection, and previous ARTs
exposure. Patients with CD4 ≤ 400 cells/𝜇L were given
Cotrimoxazole prophylaxis 960mg daily. After the initial 2
weeks of daily drug administration, antiretroviral drugs were
dispensedonamonthlybasis.Withconsistentadherenceand
followup, patients who were considered stable were given
2-monthly appointment schedules. Second line therapy was
given to clients who had clinical or virologic failure on
first line, comprising a combination of Lopinavir/ritonavir
(Kaletra, Aluvia-ALV) with either Truvada or Combivir.
These treatments were categorized as Combivir-based 1st
line (3TC/AZT with EFV or NVP); Truvada-based 1st
line (TDF/FTC with EFV or NVP); Combivir-based 2nd
line (3TC/AZT with ALV), and Truvada-based 2nd line
(TDF/FTC with ALV).
F o rt h ep u r p o s eo ft h i ss t u d yi m m u n o l o g i cc l a s s i fi c a t i o n
of the disease was done using CD4 count, based on WHO
criteria (see Table 1)[ 9]. Patients with CD4 ≥ 500 were
classified as “not-significant”; 350–499 as “mild”; 200–349 as
“advanced”; and <200 as “severe.” Further classification was
based on age as 15–24 years; 35–44 years, and ≥45 years.
This is also in line with classification used in peer-reviewed
literature [2, 6, 10].
The endpoint in our study was mortality from all causes,
although the study did not consider individual causes of
death. Deaths were registered from hospital records or
reported by relatives through home visits or phone calls.
Where the actual date was unknown, the date of last follow-
up visit was used. Right censored events were subjects
lost to followup (LTFU), defined as a patient who missed
appointmentformorethan6monthsandcouldnotbetraced.
Th e i rd a t eo fl a s tf o l l o w - u pv i s i tw a su s e da st h ec e n s o r i n g
date. Also, patients who were alive at the end of the study
period were censored on October 25, 2013. Patients who
were transferred to other facilities during this period were
excluded in the analysis.
2.3. Statistical Analysis. Data analysis was done using SAS
version 9.3. (SAS Institute Inc., Cary, NC, USA). Kaplan-
M e i e rm o d e l sw e r eu s e dt oe s t i m a t es u r v i v a ld u r i n gA R T
care and log rank tests to compare survival curves among
differentgroups.Coxproportionalhazardsmodelswereused
to identify independent predictors of mortality and calculateAIDS Research and Treatment 3
Table 1: WHO staging of HIV based on CD4 cells count.
HIV-associated immunodeficiency
Age-related CD4 values
<11 months
(%CD4+)
12–35 months
(%CD4+)
36–59 months
(%CD4+)
>5y e a r s( c e l l s / 𝜇Lo r% C D 4 + )
None or not significant >35 >30 >25 >500
Mild 30–35 25–30 20–25 350–499
Advanced 25–29 20–24 15–19 200–349
Severe <25 <20 <15 <200 or <15%
Table 2: Baseline characteristics and associated mortality among
1069 PLWHA in Nigerian Christian Hospital.
Characteristics Number of
patients
Number of
deaths (%)
Last known status
Dead 78 (7.3%)
Alive 820 (76.9%)
Loss to followup (LTFU) 168 (15.6%)
Age group (years)
15–24 39 1 (2.5)
25–34 354 15 (4.2)
35–44 442 39 (7.0)
45+ 234 39 (13.3)
Baseline CD4 staging (cells/𝜇L)
>500 312 10 (3.2)
350–499 134 3 (2.2)
200–349 111 3 (2.7)
<200 512 62 (12.1)
Drug regimen
Combivir-based 1st line 383 15 (3.9)
Truvada-based 1st line 548 55 (10.0)
Combivir-based 2nd line 67 2 (2.0)
Truvada-based 2nd line 53 2 (3.8)
hazard ratios. The survival time was calculated in months
usingthetimeintervalbetweenthedateofcommencingART
and (1) the date of event (death) or (2) date of censoring.
Univariable Cox regression analysis was performed for the
following baseline variables: sex, age group, baseline WHO
CD4 category, and drug combination. Baseline variables
significant at 𝗼 < 0.2 level in univariable analysis were
included in the final multivariable model (see Table 2). All
other analyses were two-sided and level of significance was
set at 𝑃 < 0.05.
3. Results
Atotalof1069patientswereincludedforthisstudy,compris-
ing 738 females (69%) and 331 males (31%). The median age
inthestudywas37years;males42yearsandfemales35years,
respectively. Median survival time could not be estimated
as over 90% of the patients were censored. A total of 78
(7.3%) patients were reported dead in the 5-year period after
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Figure 1: Survival curves based on gender among patients in NCH.
enrollment in the program, while 991 (92.7%) were censored.
The dead comprised 42 females (54%) and 36 males (46%).
Based on age, the dead comprised 79.5% of persons aged
above 34 years; 15–24 years (1.3%); and 25–34 years (19.2%).
The reasons for censorship were that 168 (15.6%) were lost to
followup(LTFU)and820(76.9%)werealive,attheendofthe
60-month follow-up period. The LTFU consisted of 58 males
(34.5%) and 110 females (65.5%). Loss-to-followup was the
most common among patients aged 25–34 (36.9%) and 35–
44years(36.9%)andthelowestamongthoseaged15–24years
(4.8%). At the end of the study period, 820 patients were still
on follow-up, comprising 561 females (70.8%) and 231 males
(29.2%). Table 2 summarizes the characteristics of patients in
this study.
In the univariable analysis, sex (Figure 1), age group
(Figure 2), combination regimen (Figure 3), and baseline
CD4 count (Figure 4)w e r es i g n i fi c a n t l ya s s o c i a t e dw i t h
progression to death. Progression to death was 96% higher
among patients with baseline CD4 < 200 compared with
patients with CD4 > 500 (see Table 2). Patients on Truvada
1st line were more than twice as likely to die compared with
thoseonCombivir1stline.Therewasnosignificantdifference
in mortality for patients on Combivir- and Truvada-based
2nd line therapy (HR 1.36 95% CI 0.19–9.66). Multivariate
analysis using Cox proportional model showed that signif-
icant predictors of mortality were age group, initial CD44 AIDS Research and Treatment
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Figure 3: Survival curves based on regimen among patients in
NCH.
staging, drug regimen, and final CD4 staging. Gender was
not a confounder with the other variables, and there were
no significant interactions among the variables in the study.
Table 3 summarizes the univariate and multivariate analysis.
4. Discussion
This 5-year prospective cohort study of people living with
HIV/AIDS sheds light on survival and its determinants in a
programadministeredbyaruralNigerianhospital.Themor-
tality rate of 7.6% in this cohort is higher than that reported
by Ladep et al, but much lower than the 31% reported by a
study in northern Nigeria [6, 11]. The mortality rate was also
lowerthanthatreportedbystudiesinotherAfricancountries
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Figure 4: Survival curves based on baseline CD4 staging among
patients in NCH.
with similar settings [10]. Although this study did not focus
on the cause of death, evidence shows that mortality among
PLWHA is largely attributable to Tuberculosis coinfection,
wasting syndrome, acute bacterial infections, malignancies,
and immune reconstitution inflammatory syndrome (IRIS)
[10–12].
The proportion of patients lost to followup in this study
(15.3%) is higher than what has been reported in other
African studies such as in Cameroon (5%) and Tanzania
(9.7%), but it is comparable to the rates reported in studies
conducted in southeastern Nigeria [2, 4]. LTFU in this study
may be explained by the deplorable condition of the major
access road leading to the hospital, although this is better
reviewedinanotherpublication.Thehazardofmortalityalso
was significantly higher among people with greater disease
burden (CD4 < 200), similar to what has been reported in
literature [2, 4, 6].
Drugcombinationusinghighlyactiveantiretroviralther-
apy (HAART) has improved the survival of PLWHA [13,
14]. There is evidence that Truvada (or tenofovir-containing
regimens) may be superior to Combivir, in terms of fewer
adverse effect, improved hemoglobin, and easier dosing [14].
Mortality was almost twice more likely among patients on
Truvada-based 1st line therapy compared with Combivir-
based therapy (95% CI 1.05–3.36) (see Table 2). This is differ-
ent from what Velen et al. [7] reported, although that study
compared single-agent tenofovir, zidovudine, and stavudine.
Bendavid et al. [5] also suggested that Truvada first line had
better survival and tolerance profile when compared with
C o m b i v i r ;h o w e v e rt h a ts t u d yw a sb a s e do nm a t h e m a t i c a l
simulations [5]. Stratified analysis revealed that patients with
CD4 < 200 had the higher hazard of mortality among those
on Truvada 1st line. There was no significant difference in
mortality for patients on Combivir- and Truvada-based 2nd
line therapy (HR 1.36 95% CI 0.19–9.66). This is in line with
t h efi n d i n g sf r o maC o c h r a n er e v i e wi n2 0 1 0[ 14].AIDS Research and Treatment 5
Table 3: Hazard ratios of mortality according to predictors for PLWHA in Nigerian Christian Hospital.
Variable Unadjusted (univariate) Adjusted (multivariate)
HR (95% CI) 𝑃 HR (95% CI) 𝑃
Sex (female versus male) 0.53 (0.34–0.83) <0.01
Age group (versus 15–24 years)
25–34 years 1.59 (0.21–12.06) 0.65 1.25 (0.16–9.61) 0.83
35–44 years 2.59 (0.35–18.96) 1.89 (0.26–13.89) 0.53
45+ years 4.9 (0.63–4.06) 0.12 3.60 (0.49–26.56) 0.21
Baseline CD4 staging (versus >500 cells)
350–499 0.65 (0.18–2.36) 0.51 0.66 (0.18–2.40) 0.53
200–349 0.82 (0.23–2.97) 0.33 0.91 (0.25–3.30) 0.88
<200 1.96 (2.03–7.74) <0.01 3.61 (1.84–7.07) <0.01
Drug combination
Truvada versus Combivir 1st line 2.36 (1.33–4.19) <0.01 1.88 (1.05–3.36) 0.03
Truvada versus Combivir 2nd line 1.33 (1.36–0.19) 0.78 1.36 (0.19–9.66) 0.76
There are limitations to this study. The inability of the
study to account for switching therapy from first line to
second line regimens is considered a limitation. It would
be expected that knowing the time interval from treatment
initiation to switching therapy would give valuable clue to
outcome based on first line agents only. Also, the high rate
of censoring (being live and loss to follow-up) might have
biased the study findings. Many of the cases lost to followup
had poorer prognosis (low CD4 count); considering them
a sc e n s o r e dm a yh a v er e s u l t e di ns e l e c t i o nb i a sw h i c hc o u l d
threaten the validity of our findings. This can be improved
through intensive patient tracking and timely data manage-
ment entry. This study did not consider clinical indicators
of patient progress (clinical staging), which may be a more
suitable predictor of survival.
5. Conclusion
Thestudyhasshownthepredictorsofmortalityinacohortof
PLWHA followed for 60 months. The patient demographics
were comparable to those published in the literature for
Nigeria. Mortality in this treatment program was lower than
most reported for Nigeria and other African countries. Male
gender, CD4 < 200, Non-ART clients, and age above 45 years
were among the significant predictors of morality. Hazard of
mortality was significantly higher for patients on Truvada-
based first line regimen compared to Combivir 1st line;
patients with CD4 < 200 had worst outcome among those
on Truvada 1st line. The ART program at Nigerian Christian
Hospital has improved the survival of its clients, as it had
m o r t a l i t yo fl e s st h a n8 %o ft h es t u d yp o p u l a t i o na l t h o u g h
m o r et h a n1 5 %w e r el o s tt of o l l o w - u p .
It is recommended that managers of ART programs in
similar settings should intensify patient follow-up, especially
formalesandthosewithlowCD4counts,inordertoimprove
survival. This hospital would need to work towards reducing
the rate of loss to follow-up. Further research will be needed
to further test the clinical efficacy of Truvada-based regimen,
using other outcomes such as progression of CD4 counts.
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